Marketing-authorisation holder
Gland Pharma Limited
49 medicines in 2 countries, as authorisation holder and manufacturer.
Group structure
Part of
GlandPharmaceutical groupOther companies in the group
Headquarters not stated1
Groups are put together by Prognia from the names regulators publish and from company links; they are not an official corporate structure.
Medicines
Every medicine in the registers under its name, current ones first.
1–25 of 49
| Medicine | Substance | Country | Status | Authorised |
|---|---|---|---|---|
| ALCAFTADINE0.25% · Solution/drops | Alcaftadine | United States | Marketed | 2023 |
| ALLOPURINOL SODIUM500mg base/vial · Injectable | Allopurinol | United States | Marketed | 2004 |
| ANGIOTENSIN ll ACETATE2.5mg base/ml (eq 2.5mg base/ml) · Solution | Angiotensin ii | United States | Marketed | 2025 |
| ARSENIC TRIOXIDE10ml | 1mg/ml | 2mg/ml · Injectable | Arsenicum album | United States | Marketed | 2008 |
| AZELASTINE HYDROCHLORIDE0.05% · Solution/drops | Azelastine | United States | Marketed | 2009 |
| CANGRELOR50mg/vial · Powder | Cangrelor | United States | Marketed | 2025 |
| CASPOFUNGIN ACETATE50mg/vial | 70mg/vial · Powder | Caspofungin | United States | Marketed | 2016 |
| DECITABINE50mg/vial · Injectable | Decitabine | United States | Marketed | 2013 |
| DEXMEDETOMIDINE HYDROCHLORIDE1mg base/250ml (eq 4mcg base/ml) | 200mcg base/2ml (eq 100mcg base/ml) | 200mcg base/50ml (eq 4mcg base/ml) | 400mcg base/100ml (eq 4mcg base/ml) | 80mcg base/20ml (eq 4mcg base/ml) · Injectable | Dexmedetomidine | United States | Marketed | 2014 |
| FLUPHENAZINE DECANOATE25mg/ml · Injectable | Fluphenazine | United States | Marketed | 1987 |
| LATANOPROSTENE BUNOD0.024% · Solution/drops | Latanoprostene bunod | United States | Marketed | 2025 |
| LEVOFLOXACIN500mg/20ml (eq 25mg/ml) | 5mg/ml | 750mg/30ml (eq 25mg/ml) · Injectable | Levofloxacin | United States | Marketed | 2005 |
| NETARSUDIL MESYLATE0.02% · Solution | Netarsudil | United States | Marketed | 2024 |
| POSACONAZOLE300mg/16.7ml (18mg/ml) · Solution | Posaconazole | United States | Marketed | 2022 |
| SELENIOUS ACID12mcg selenium/2ml (eq 6mcg selenium/ml) | 600mcg selenium/10ml (eq 60mcg selenium/ml) | 60mcg selenium/ml (eq 60mcg selenium/ml) · Solution | Selenious acid | United States | Marketed | 2019 |
| TEMSIROLIMUS25mg/ml (25mg/ml) · Solution | Temsirolimus | United States | Marketed | 2018 |
| VANCOMYCIN HYDROCHLORIDE1.25GM BASE/VIAL | 1.5GM BASE/VIAL | 1.75GM BASE/VIAL | 100GM BASE | 250MG BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | 2GM BASE/VIAL | 750MG BASE/VIAL · Powder | Vancomycin | United States | Marketed | 2016 |
| VASOPRESSIN200units/10ml (20units/ml) | 20units/100ml (0.2units/ml) | 20units/ml (20units/ml) · Solution | Vasopressin (argipressin) | United States | Marketed | 2020 |
| VASOPRESSIN IN DEXTROSE 5%20units/100ml (0.2units/ml) | 40units/100ml (0.4units/ml) · Solution | Vasopressin (argipressin) | United States | Marketed | 2024 |
| VORICONAZOLE200mg/vial · Powder | Voriconazole | United States | Marketed | 2012 |
| ZOLEDRONIC4mg base/100ml · Injectable | Zoledronic acid | United States | Marketed | 2018 |
| Azithromycin TBM | Azithromycin | Saudi Arabia | Authorised | |
| Bortezomib BOS | Bortezomib | Saudi Arabia | Authorised | |
| CASPOFUNGIN 50MG VIAL | Caspofungin | Saudi Arabia | Authorised | |
| CASPOFUNGIN 70MG VIAL | Caspofungin | Saudi Arabia | Authorised |